IP Library › Granted Patent US 10,676,788
Granted Patent B2
US 10,676,788 · App. 15/600,665 · Granted Jun 9, 2020

Modified nucleotide reagents

Inventors: Gene Shen (Santa Clara, CA); Stephen Yue (Eugene, OR); Lubomir Sebo (Hayward, CA); Louis Brogley (Santa Cruz, CA)
Assignee: Pacific Biosciences of California, Inc.
C12Q1/6869C07H19/052C07H19/207C07H21/04C09B23/06C09B23/083C09B69/00C12Q1/6876
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,788
App. No.
15/600,665
Granted
Jun 9, 2020
Kind
B2
Abstract

Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.

Claims (42)

1. A nucleotide compound of structural formula (I):

wherein

L is a nucleotide linker element comprising at least one affinity modulating element; wherein the at least one affinity modulating element is an aromatic spacer element;

P is a polyphosphate element;

Nu is a nucleoside element;

X is a multivalent central core element;

B″ is a terminal coupling element;

n is an integer from 1 to 4; and

o is 0 or 1.

2. The nucleotide compound of claim 1 , wherein the at least one affinity modulating element decreases the K m of a nucleotide-dependent enzyme for the nucleotide compound or increases the enzymatic rate of the nucleotide-dependent enzyme.

3. The nucleotide compound of claim 1 , wherein the aromatic spacer element is a substituted or unsubstituted monocyclic, bicyclic, tricyclic, or tetracyclic aromatic moiety.

4. The nucleotide compound of claim 3 , wherein the aromatic spacer element optionally comprises at least one anionic substituent.

5. The nucleotide compound of claim 4 , wherein the aromatic spacer element optionally comprises at least two anionic substituents.

6. The nucleotide compound of claim 4 , wherein the optional at least one anionic substituent is —SO 3 H.

7. The nucleotide compound of claim 3 , wherein the aromatic spacer element is represented by structural formula (II):

wherein

the A-ring and the B-ring is each independently a 5-7 atom cyclic structure, wherein at least one of the A-ring or the B-ring is aromatic; and

the A-ring or the B-ring optionally comprises at least one anionic substituent.

8. The nucleotide compound of claim 7 , wherein the optional at least one anionic substituent is —SO 3 H.

9. The nucleotide compound of claim 3 , wherein the aromatic spacer element is represented by one of the following structural formulae:

wherein

one of the A 1 , A 2 , A 3 , and A 4 groups is

 and the other groups are —CH 2 — or a bond; and

R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently H or an anionic substituent.

10. The nucleotide compound of claim 9 , wherein the anionic substituent is —SO 3 H.

11. The nucleotide compound of claim 9 , wherein the aromatic spacer element is represented by structural formula (IIC) or (IIC′):

12. The nucleotide compound of claim 9 , wherein the aromatic spacer element is represented by one of the following structural formulae:

13. The nucleotide compound of claim 1 , wherein L further comprises an alkyl linker group, optionally comprising an amide bond.

14. The nucleotide compound of claim 1 , wherein L further comprises a triazole.

15. The nucleotide compound of claim 1 , wherein B″ comprises a biotin moiety.

16. The nucleotide compound of claim 15 , wherein B″ comprises a bis-biotin moiety.

17. The nucleotide compound of claim 1 , wherein o is 1.

18. The nucleotide compound of claim 17 , wherein n is 2.

19. The nucleotide compound of claim 17 , wherein X comprises a polyamine moiety.

20. The nucleotide compound of claim 1 , wherein o is 0 and n is 1.

21. The nucleotide compound of claim 1 , wherein the compound does not contain a dye.

22. The nucleotide compound of claim 1 , wherein L further comprises a shield element.

23. A nucleotide reagent composition comprising an avidin protein and the nucleotide compound of claim 1 .

24. The nucleotide compound of claim 1 , wherein at least one B″ comprises a reactive functional group.

25. The nucleotide compound of claim 24 , wherein at least one B″ comprises a residue derived from a reactive functional group.

26. The nucleotide compound of claim 25 , wherein the residue derived from a reactive functional group is an amide moiety.

27. The nucleotide compound of claim 25 , wherein the residue derived from a reactive functional group results from a click reaction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2017
From: SHEN, GENE; YUE, STEPHEN; SEBO, LUBOMIR; BROGLEY, LOUIS
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 043202/0624 →
Continuity (3)
Continuation In Part 15357958 · Nov 21, 2016
Provisional Application 62258414 · Nov 20, 2015
Related Publication 20170321268A1 · Nov 9, 2017
Cited By (9)
US 12,259,391 US 12,312,377 US 12,360,114 US 12,422,438 US 12,528,083 US 12,545,901 US 12,577,607 US 12,618,845 US 12,655,467